Close

Drug Research

Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal

Roche-owned Genentech has entered into a major collaboration with Earendil Labs to discover and develop bispecific antibodies targeting oncology, in a deal valued at up to $1.5 billion. Deal Structure and Financial Terms Under the terms of the agreement, Earendil will...

AbbVie and Iambic Partner to Accelerate AI Drug Discovery in Immunology, Neuroscience and Oncology

AbbVie and Iambic have entered into a multiyear collaboration focused on AI drug discovery across three major therapeutic areas — immunology, neuroscience, and oncology. The partnership brings together Iambic's molecular superintelligence platform and AbbVie's established drug discovery expertise, with...

Lot-to-Lot Reproducibility in HPLC Column Performance: Why Pharmaceutical QC Depends on Statistical Consistency

High-performance liquid chromatography (HPLC) is key to achieving statistical consistency, which is a cornerstone of pharmaceutical quality control (QC). Column performance is vital to the technique's effectiveness, underscoring the importance of lot-to-lot reproducibility when sourcing HPLC columns for drug...

UK Launches £45M Research Partnership Funding and Unveils First Workplace Health System Plan

The UK's National Institute for Health and Care Research (NIHR) has opened the first funding round for its Strategic Infrastructure Partnerships programme, inviting applications for a share of £45 million aimed at accelerating the translation of early-stage medical discoveries...

How Refurbished Gear Is De-Risking Early-Stage Pharma R&D

Early-stage pharmaceutical companies invest heavily in discovery and development without knowing whether a candidate will reach clinical trials and commercialization. This uncertainty makes every spending decision critical, particularly when laboratory equipment represents substantial expenses across analytical testing and sample...

Novo Nordisk and Orbis Medicines Partner on Oral Therapies for Cardiometabolic Diseases

Danish pharmaceutical company Novo Nordisk and biotechnology developer Orbis Medicines have entered into a drug discovery and licensing agreement valued at up to $1.4 billion to develop oral therapies for cardiometabolic diseases. The program aims to advance oral alternatives...

FDA Opens Door to Innovative Approaches for Psychedelic Drug Development Amid Mental Health Crisis

Senior officials at the US Food and Drug Administration have signaled that the agency is open to novel and innovative approaches in the clinical development of psychedelic drugs, citing the worsening mental health crisis across the United States. The...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »